Lipid mediators in bronchiectasis
Research type
Research Study
Full title
Investigating the role of lipid mediators in bronchiectasis
IRAS ID
140128
Contact name
Adam Hill
Contact email
Research summary
Bronchiectasis is a chronic disabling condition, where patients suffer daily cough, sputum production and recurrent chest infections. However, this remains an 'orphan' disease with limited research done to date.
In bronchiectasis, there is an ongoing cycle of infection and inflammation in the airways with more than two-thirds of patients being infected at all times, leading to more inflammation. The inflammation that occurs is meant to clear the infection from the airways but in bronchiectasis this does not occur.
Preliminary experiments in our centre has shown that there is lack of the lipid, Lipoxin(LX)A4, in bronchiectasis. LXA4 is an important agent that in health switches off this process of inflammation. This research offers a new non-antibiotic target to help treat patients with bronchiectasis as there are very few effective treatments available for this condition.REC name
West of Scotland REC 3
REC reference
14/WS/1080
Date of REC Opinion
10 Oct 2014
REC opinion
Further Information Favourable Opinion